IFN beta-1a for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
Kalil (ACTT-3) NCT04492475		RCT	IFN beta-1a	placebo	COVID-19 severe or critically	some concern	487/482	inconclusive	inconclusive 1 % decrease in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Davoudi-Monfared IRCT20100228003449N2		RCT	IFN beta-1a	standard of care	COVID-19 severe or critically	high	46/46	suggested	suggested 70 % decrease in death D28 but with a low degree of certainty due to high risk of bias suggested 63 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias inconclusive 10 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis